



2010

2010

2009 3

2010 1 1 2010 12 31

2010

2012

(Global Reporting Initiative, GRI)

G3

www.fosunpharma.com

(PEFC)

www.fosunpharma.com

2010

EHS


2010

15

2010

2010






2

3

6

10

13



14

15

16

18


18

19

20

23

29



30

31

31

32

33

33

33


34

35

35

35

37



38

40

40

40



45

| | |
|-----|----|
| EHS | 46 |
| | 46 |
| | 46 |
| | 49 |
| | 49 |
| | 49 |
| | 50 |

53

| | |
|--|----|
| | 54 |
| | 55 |
| | 55 |
| | 55 |
| | 56 |
| | 58 |
| | 59 |

61

| | |
|--|----|
| | 62 |
| | 62 |
| | 62 |
| | 63 |
| | 64 |
| | 64 |
| | 65 |

67

68

GRI 70

SGS 76

78

80

82

(
) 5 25
002412

2007

50%

76.3%

2010 ,

2010 6 9

2010 11 4

WHO-PQ

WHO

GMP

WHO-GMP

11%y

2010 12 28

Ltd.

Chindex Medical
MPD

2010 7 28

200

2010 10 12 ,
1.22

55%



复星医药与美中互利医疗器械合资公司签约仪式 FOSUNPHARMA & CHINESE




| | |
|---|---|
| 1 | 4 |
| 2 | |
| 3 | 5 |

- 1
- 2
- 3
- 4
- 5





2010 5 18 5 31 63,539.20
 16 29
 2010 9 16 2009
 76.14 100 471 A
 (600196) 5 6
 2010 5 4 RKS
 2009
 AA 76.14 78.71
 78.49 2008
 6.55 3,182 20.6 / 6.35



600196 1994 1998 8
1998 12 39
39.59 %








2009 2010





战略管理






| 2009 | 2010 | 2015 |
|------|---------|------|
| 1. | 1. | 1. |
| 2. | 2. EHS | 2. |
| 3. | 3. 2010 | 3. |
| 4. | 4. | 4. |
| | 5. | 5. |
| | | 6. |
| | | 7. |

| 2009 | 2010 | 2015 |
|--------|---------|------|
| 1. | 1. | 1. |
| 2. GMP | 2. | 2. |
| 3. | 3. 2010 | 3. |
| 4. | 4. | 4. |
| 5. | 5. " | 5. |
| 6. | 6. | 6. |






EHS
/

2010

Pre-IPO





| | |
|--|--|
| | |
| | |
| | |
| | |
| | |



/

2010 4 26

2012

2008 5

2011 1 1

2012

1 1

18

2011

2010

50

/



2010

2010

34

38

2009

86%

3

2010



2010

460

2010

13

/

GMP

2010

307

28

2010

2010

2010

2006-h(2 / ,

2010

2010

2010





FOSUNPHARMA 复星医药

2010年12月31日 16:16:34

| 年份 | 营业收入 (亿元) | 净利润 (亿元) | 每股收益 (元) | 净资产收益率 (%) |
|------|-----------|----------|----------|------------|
| 2010 | 110.00 | 11.00 | 0.40 | 15.00 |
| 2009 | 100.00 | 10.00 | 0.35 | 14.00 |
| 2008 | 90.00 | 9.00 | 0.30 | 13.00 |
| 2007 | 80.00 | 8.00 | 0.25 | 12.00 |
| 2006 | 70.00 | 7.00 | 0.20 | 11.00 |
| 2005 | 60.00 | 6.00 | 0.15 | 10.00 |
| 2004 | 50.00 | 5.00 | 0.10 | 9.00 |
| 2003 | 40.00 | 4.00 | 0.05 | 8.00 |
| 2002 | 30.00 | 3.00 | 0.02 | 7.00 |
| 2001 | 20.00 | 2.00 | 0.01 | 6.00 |
| 2000 | 10.00 | 1.00 | 0.00 | 5.00 |



2010

2005

2010

2010

15

2010

5

10

200

464

4136

2010

100

60


11000

2010

2010

2010











| | | | | |
|---------|------------|------|--------|---------|
| 2010 | 455,542.17 | 2009 | 17.64% | 114,045 |
| 120,195 | 86,365 | | | |

2008 2010





2010

| 2010 | |
|------|---------|
| | 89.97 1 |
| | 34.67 1 |
| | 61.47 1 |
| V- | 27.15 1 |
| | 29.71 1 |
| | 25.66 1 |
| | 19.71 2 |
| | 24.67 2 |
| | 12.06 2 |
| | 18.53 2 |

IMS

42,787.39 113,026 2009 8.68%

2009 13.33%

25.03%

31.45%

401

401

2010 22 3


2010 169

MDC 2009

12

2009

26



2010 3 2009

50



2010 HIV 60%

2010 2009 40%

2009

2009

H PV 300

20

2010



Chindex International, Inc.

Pre-IPO



Chindex Medical Limited

2010


50%

2010

2010



11 1998 1165% 2009 4.3131
9.94 2009 27.2% 2010 57,564
2010







2010

2010

GMP()
OOS/



OOT CAPA

GMP

2010

GMP

| | |
|--|--|
| | |
| | |
| | |
| | |



GSP

SOP

| | USP EP ICH | FDA EDQM GMP SFDA GMP |
|-----|------------|-----------------------|
| GAP | | GMP |
| | | 1 2 GMP |
| | | OOS |
| | | GMP |
| | | AIB ISO9001 ISO20002 |

1+N

4

1+N

15

1+N

1+N

231

27



6400

2005
2010

1900

1+N

| | | |
|--|------|------|
| | 15 | 6400 |
| | 2008 | 1+N |
| | 1+N | 17 |
| | 7000 | |







FOSUNPHARMA
复星医药

EHS



EHS

EHS

EHS

EHS

Environment

Health

Safety



2010


2011

2010

6


800ÜY/ 3#1b>)2\$! ÖÄÄ

1p 0Đí;Ÿ



2010

| | | | 6000 | 11 | 5.5% |
|--|----|------|-----------|------|------|
| | | | 4.5% | 4950 | |
| | | | | | |
| | | 2009 | 20000 | | 81% |
| | | | ISO-14001 | | |
| | 50 | | | | |



2011

500

100%

EHS

100%

2010
2009 71%
4.37%

2010

GMP

3

1

100%

2009

2010


| | | | |
|--|------|------|---------|
| | 7 | 12 | 71.43% |
| | 1076 | 1123 | 4.37% |
| | 9 | 8 | -11.11% |

1+N
32
1+N
30%
2010
2010
2010
2010



2010









11484 2009 19.5% 55.6% 2010 12 31 25% 20% 2010

30 50 50%

2010 14% 2009

| 2010 | 11484 | 5975 | 5509 |
|------|-------|------|------|
| 2009 | 9611 | 5088 | 4523 |
| 2008 | 8580 | 4617 | 3963 |



| | | | | | |
|------|----|-----|------|------|------|
| 2010 | 42 | 327 | 2038 | 2342 | 6735 |
| 2009 | 27 | 262 | 1626 | 1859 | 5837 |
| 2008 | 23 | 211 | 1231 | 1491 | 5623 |

| | | | | | | |
|------|-----|------|------|------|-----|------|
| 2010 | 493 | 4684 | 3217 | 1667 | 284 | 1139 |
| 2009 | 340 | 4239 | 2687 | 1275 | 241 | 829 |

| | 20 | 20 30 | 30 40 | 40 50 | 50 55 | 55 60 | 60 |
|------|-----|-------|-------|-------|-------|-------|----|
| 2010 | 389 | 3949 | 3285 | 2728 | 688 | 397 | 48 |
| 2009 | 376 | 3550 | 2883 | 1717 | 715 | 322 | 48 |



900 95% 92 2010
 2010 67.5 40%



2010

HR


TTT

2010

16

2009

20



2009

2010



2010

HR

EHS

HR

2010
24%
40%

MT 2010

44
8
141

2010 12.82%

2010 9

1+N 1+N

6 1500

22 12 31


2010 12

| | 2010 | 2009 |
|---|--------|--------|
| | 18.84% | 25% |
| - | 29.41% | 40.63% |
| - | 50.00% | 18.75% |
| | 9.09% | 15.63% |
| | 24.31% | 21.30% |

/

| 2007 | 18.96% |
|------|--------|
| 2008 | 17.20% |
| 2009 | 14.22% |
| 2010 | 12.82% |






2010 8

| | |
|----|--|
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |

2010







15



2010

2010 6 15

3

5





| | | | | | |
|------|------|------|-------|-------|-------|
| 2010 | 6 | | | | |
| 2010 | 7 | 26 | 2010 | | |
| 2010 | 7 | 27 | | 20 | 2010 |
| | | | 10 | | |
| 2010 | 8 | 17 | | 10 | |
| 2010 | 9 | 16 | | 2010 | |
| 2010 | 9 | 16 | 2009 | | |
| | | | 76.14 | | |
| 2010 | 9 | 20 | | | |
| 2010 | 9 | 21 | 2010 | 20 | 2 010 |
| | | | 5 0 | | |
| 2010 | 10 | 24 | | | |
| | 2010 | 10 | | 2010 | |
| 2010 | 11 | 13 | | 2 010 | |
| 2010 | 11 | 2 0 | | | " |
| | | | " | | |
| 2010 | 11 | 2 3 | | | |
| | | 2010 | | | |
| | | 2010 | | | |
| | | 2010 | 2010 | | |

2010

| | 2010 | 2009 | 2008 |
|---|------|------|------|
| | 4.42 | 0.21 | 3.24 |
| | 0.46 | 1.35 | 0.37 |
| | 0.2 | 0.20 | 0.18 |
| % | 4.99 | 7.18 | 8.28 |

| | 2010 | 2009 | 2008 |
|--|---------|---------|---------|
| | 118,179 | 321,914 | 847,054 |
| | 6,948 | 6,115 | 3,823 |
| | 798 | 852 | 1,011 |
| | 20,161 | 70,040 | 7,474 |
| | 86,365 | 249,820 | 690,857 |

| | 2010 | 2009 | 2008 |
|--|---------|---------|---------|
| | 455,542 | 387,226 | 377,323 |
| | 114,045 | 321,203 | 80,756 |
| | 6,948 | 6,115 | 3,823 |
| | 798 | 852 | 1,011 |
| | 24 | 336 | 1,011 |
| | 120,195 | 326,467 | 83,568 |
| | 20,161 | 70,040 | 7,474 |
| | 100,034 | 256,427 | 76,093 |
| | 86,365 | 249,820 | 69,086 |
| | 13,669 | 6,607 | 7,007 |

| 2010 | 11484 | 5975 | 5509 |
|------|-------|------|------|
| 2009 | 9611 | 5088 | 4523 |
| 2008 | 8580 | 4617 | 3963 |

| 2010 | 784892 | 68.35 |
|------|--------|-------|
| 2009 | 413818 | 43.06 |
| 2008 | 354569 | 41.33 |

2008 -2010

| | 2008 | 2009 | 2010 |
|--|--------|--------|--------|
| | 37,286 | 45,255 | 57,564 |

| | 2008 | 2009 | 2010 |
|---|------|------|------|
| | 128 | 101 | 111 |
| | 10 | 4 | 4 |
| / | 19 | 6 | 12 |
| | 11 | 14 | 5 |

(GRI)

| | |
|-----|-------|
| 1.1 | 3 |
| 1.2 | 14-23 |

| | |
|------|-------------|
| 2.1 | 10-11 |
| 2.2 | 11 31-33 |
| 2.3 | 10-11 31-33 |
| 2.4 | |
| 2.5 | 10-11 16-17 |
| 2.6 | 18-23 |
| 2.7 | 16-17 30-34 |
| 2.8 | 16-17 30-34 |
| 2.9 | 18-23 |
| 2.10 | 6 67 |

| | |
|------|------|
| 3.1 | 2 |
| 3.2 | 2 |
| 3.3 | 2 |
| 3.4 | 2 80 |
| 3.5 | 2 |
| 3.6 | 2 |
| 3.7 | 2 |
| 3.8 | 2 |
| 3.9 | 2 |
| 3.10 | 69 |

| | | | | |
|------|--|--|-------|----------|
| 3.11 | | | 2 | 69 |
| 3.12 | | | | 70-75 |
| 3.13 | | | | 76-78 |
| 4.1 | | | | 18-23 |
| 4.2 | | | | 18-23 |
| 4.3 | | | | 18-23 |
| 4.4 | | | | 18-26 |
| 4.5 | | | | 56-59 |
| 4.6 | | | | 18-26 |
| 4.7 | | | | 14-26 |
| 4.8 | | | | 14-26 |
| 4.9 | | | 10-11 | 14-26 |
| 4.10 | | | | 18-26 |
| 4.11 | | | | 18-23 |
| 4.12 | | | 14-26 | 40 46-50 |
| 4.13 | | | | 26 50 |
| 4.14 | | | | 23-26 |
| 4.15 | | | | 23-26 |
| 4.16 | | | | 23-26 |
| 4.17 | | | 23-26 | 80-81 |

| | | |
|-----|-------|-------|
| EC1 | 30-35 | 68-69 |
| EC2 | | 46-50 |
| EC3 | 35 | 55 58 |
| EC4 | | 31 |
| EC5 | 35 | 55 69 |
| EC6 | | 40-44 |
| EC7 | | 54-59 |
| EC8 | | 62-65 |
| EC9 | | 30-35 |

| | | |
|------|--|-------|
| EN1 | | 46-47 |
| EN2 | | 48 |
| EN3 | | 46-48 |
| EN4 | | 46-48 |
| EN5 | | 46-49 |
| EN6 | | 46-51 |
| EN7 | | 46-47 |
| EN8 | | 46-48 |
| EN9 | | 46-48 |
| EN10 | | 46-48 |
| EN11 | | |
| EN12 | | |
| EN13 | | |

| | | |
|------|---------------|-------|
| EN14 | | 48 |
| EN15 | IUCN Red List | |
| EN16 | | 46-48 |
| EN17 | | 46-48 |
| EN18 | | 46-48 |
| EN19 | | |
| EN20 | | 46-48 |
| EN21 | | 46-48 |
| EN22 | | 48 |
| EN23 | | |
| EN24 | II III VIII | I |
| EN25 | | |
| EN26 | | 46-50 |
| EN27 | | 48 |
| EN28 | | 46 |
| EN29 | | 46-50 |
| EN30 | | 46 |

| | | |
|-----|--|-------|
| LA1 | | 54 |
| LA2 | | 54 58 |
| LA3 | | 19 |

| | |
|------|----------|
| LA4 | 54-59 |
| LA5 | 54-59 |
| LA6 | 49 54-59 |
| LA7 | 49 |
| LA8 | 62 |
| LA9 | 49 |
| LA10 | 56 |
| LA11 | 54-59 |
| LA12 | 55 |
| LA13 | 54-55 |
| LA14 | 54-59 |

| | |
|-----|----------|
| HR1 | 23-26 |
| HR2 | 22-23 |
| HR3 | 54-59 |
| HR4 | 55 |
| HR5 | 24 58 |
| HR6 | 49 54-59 |
| HR7 | 49 |
| HR8 | 49 56 |
| HR9 | |

| | | |
|-----|-------|-------|
| SO1 | 23-26 | 62-65 |
| SO2 | | 62 |
| SO3 | | 62 |
| SO4 | 20 | 62 |
| SO5 | 24-26 | 62-65 |
| SO6 | | 63 |
| SO7 | 20 | 62 |
| SO8 | | 46 |

| | | |
|-----|-------|-------|
| PR1 | | 38-43 |
| PR2 | | |
| PR3 | 30-34 | 38-43 |
| PR4 | | |
| PR5 | 23 | 38 40 |
| PR6 | 38-43 | 62 |
| PR7 | | |
| PR8 | | 23 |
| PR9 | | |



2010

SGS
SGS

2010

2010

2010

SGS

2010

•
•

2006 (GRI G3)

/

SGS

140
SGS

SAI SA8000

ISO14001

OHSAS18001

GRI

2010

GRI

2010

GRI G3

2010

GRI

GRI

,



SGS

SGS

SGS

2011 3 29

900 B-11

WWW.CN.SGS.COM

2010

2008

2008

2009

2010

1

2

3

4

5

EHS

2010

1

2





2

200010

86 21 63325080

86 21 63323318

pr@fosunpharma.com

www.fosunpharma.com

2010

1
2
3
4
5

| | |
|--------------------------|--------------------------|
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |



